La Jolla-based biopharmaceuticals firm Regulus Therapeutics, which is developing microRNA-based biopharmaceuticals aimed at oncology, fibrosis, hepatitis C and metabolic diseases, said it has raised $80.9M in total proceeds from its IPO, a private placement, and convertible note. The firm said $50.9M came from its sale of common stock, $25.0M in a private placement to AstraZeneca AB, and $5.0M from a convertible note sale to Biogen Idec. The firm said those funds will enable it to "executive its current strategic objectives" for the foreseeable future.
Top NewsMonday, November 5, 2012
Regulus Gets $80.9M In Financing Efforts